देश: संयुक्त राज्य
भाषा: अंग्रेज़ी
स्रोत: NLM (National Library of Medicine)
ZOLPIDEM TARTRATE (UNII: WY6W63843K) (ZOLPIDEM - UNII:7K383OQI23)
Mylan Institutional Inc.
ZOLPIDEM TARTRATE
ZOLPIDEM TARTRATE 5 mg
ORAL
PRESCRIPTION DRUG
Zolpidem tartrate tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem tartrate tablets have been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies (14)] . The clinical trials performed in support of efficacy were 4 to 5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. Zolpidem tartrate tablets are contraindicated in patients with known hypersensitivity to zolpidem. Observed reactions include anaphylaxis and angioedema [see Warnings and Precautions (5.3)] . There are no adequate and well-controlled studies of zolpidem tartrate tablets in pregnant women. Studies in children to assess the effects of prenatal exposure to zolpidem have not been conducted; however, cases of severe neonatal respiratory depression have been reported when zolpidem was used at the end of pregnancy, especially when taken with other CNS depressants. Children
Zolpidem Tartrate Tablets, USP are available containing 5 mg or 10 mg of zolpidem tartrate, USP. The 5 mg tablets are lavender, film-coated, round, unscored tablets debossed with M over Z1 on one side of the tablet and blank on the other side. They are available as follows: NDC 51079-724-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 10 mg tablets are lavender, film-coated, round, unscored tablets debossed with M over Z2 on one side of the tablet and blank on the other side. They are available as follows: NDC 51079-725-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] PHARMACIST: Dispense a Medication Guide with each prescription.
Abbreviated New Drug Application
ZOLPIDEM TARTRATE- ZOLPIDEM TARTRATE TABLET, FILM COATED Mylan Institutional Inc. ---------- MEDICATION GUIDE Zolpidem Tartrate Tablets, USP CIV (zole pi' dem tar' trate) Read the Medication Guide that comes with zolpidem tartrate tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about zolpidem tartrate tablets? • Do not take more zolpidem tartrate tablets than prescribed. • Do not take zolpidem tartrate tablets unless you are able to stay in bed a full night (7 to 8 hours) before you must be active again. • Take zolpidem tartrate tablets right before you get in bed, not sooner. Zolpidem tartrate tablets may cause serious side effects, including: • After taking zolpidem tartrate tablets, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with zolpidem tartrate tablets. Reported activities include: • driving a car ("sleep-driving") • making and eating food • talking on the phone • having sex • sleep-walking Call your healthcare provider right away if you find out that you have done any of the above activities after taking zolpidem tartrate tablets. Do not take zolpidem tartrate tablets if you: • drank alcohol that evening or before bed • took another medicine to help you sleep What are zolpidem tartrate tablets? Zolpidem tartrate tablets are a sedative-hypnotic (sleep) medicine. Zolpidem tartrate tablets are used in adults for the short-term treatment of a sleep problem called insomnia (trouble falling asleep). It is not known if zolpidem tartrate tablets are safe and effective in children under the age of 18 years. Zo पूरा दस्तावेज़ पढ़ें
ZOLPIDEM TARTRATE- ZOLPIDEM TARTRATE TABLET, FILM COATED MYLAN INSTITUTIONAL INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ZOLPIDEM TARTRATE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZOLPIDEM TARTRATE TABLETS. ZOLPIDEM TARTRATE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1992 RECENT MAJOR CHANGES Dosage and Administration, Dosage in Adults ( 2.1) 8/2016 Dosage and Administration, Special Populations ( 2.2) 12/2016 Warnings and Precautions, CNS Depressant Effects and Next-Day Impairment ( 5.1) 8/2016 Warnings and Precautions, Precipitation of Hepatic Encephalopathy ( 5.7) 12/2016 INDICATIONS AND USAGE Zolpidem tartrate tablets, a gamma-aminobutyric acid (GABA) A agonist, are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. ( 1) DOSAGE AND ADMINISTRATION Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily. ( 2.1) Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 mg or 10 mg for men, immediately before bedtime with at least 7 to 8 hours remaining before the planned time of awakening. ( 2.1) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 5 mg for men and women. ( 2.2) Lower doses of CNS depressants may be necessary when taken concomitantly with zolpidem tartrate tablets. ( 2.3) The effect of zolpidem tartrate tablets may be slowed if taken with or immediately after a meal. ( 2.4) DOSAGE FORMS AND STRENGTHS 5 mg and 10 mg tablets. Tablets not scored. ( 3) CONTRAINDICATIONS Known hypersensitivity to zolpidem. ( 4) WARNINGS AND PRECAUTIONS CNS Depressant Effects: Impairs alertness and motor coordination. Instruct patients on correct use. ( 5.1) Need to evaluate for co-morbid diagnoses: Reevaluate if insomnia persists after 7 to 10 days of use. ( 5.2) Severe anaphylactic/anaphylactoid reactions: Angioedema and anaphylaxis have been reported. Do not rec पूरा दस्तावेज़ पढ़ें